Magnesium and Migraines: An Evidence-Based Review

Of all the supplement-condition relationships in the migraine literature, magnesium and migraines stands out as one of the better-supported: magnesium deficiency is measurably more prevalent in migraine patients than in headache-free controls, intravenous magnesium is an established clinical treatment for acute migraine in emergency settings, and multiple randomized controlled trials have tested oral supplementation for prevention with consistently positive results.

The Evidence Base: From IV Rooms to Oral Trials

The clinical case for magnesium in migraines builds from three distinct bodies of evidence.

Below is a summary of magnesium doses studied for migraine prevention and acute treatment.

Use Case	Dose	Form	Evidence Level	Notes
Prevention (prophylaxis)	400–600 mg/day	Citrate or glycinate	Moderate (multiple RCTs)	Takes 8–12 weeks to assess effect
Acute IV treatment	1 g IV	Magnesium sulfate	Moderate	Hospital/clinical setting only
Menstrual migraine	360 mg/day (luteal phase)	Citrate	Limited–Moderate	Cycle-based targeted protocol
Paediatric prophylaxis	9 mg/kg/day	Oxide (studied)	Limited	Requires paediatric supervision

Deficiency prevalence data: Multiple studies measuring ionized magnesium in migraine patients during and between attacks have found substantially lower levels compared to non-migraine controls. Serum magnesium is a poor proxy — less than 1% of body magnesium is in the blood — but ionized serum magnesium, intracellular measurements, and cerebrospinal fluid sampling have all shown consistent deficiency signals in migraine cohorts. Estimates of magnesium deficiency prevalence in chronic migraine patients range from 30% to 50%, substantially higher than the general population baseline. As covered in Magnesium Deficiency: 7 Signs, standard blood tests routinely miss intracellular deficiency.

IV magnesium for acute treatment: Intravenous magnesium sulfate has been used in emergency migraine management since the 1990s. Several controlled trials have demonstrated that IV magnesium (1–2g magnesium sulfate infused over 15–30 minutes) reduces acute migraine pain scores and associated symptoms. Response rates are highest in patients with aura and in those with documented low ionized serum magnesium at presentation. This is not a fringe application: the American Academy of Emergency Medicine has published on IV magnesium use for acute migraine, and it appears in various emergency medicine protocols.

Oral supplementation for prevention: Three key randomized controlled trials have tested oral magnesium for migraine prevention, with follow-up evidence from additional smaller studies and a systematic review. The primary trials used magnesium doses between 300–600 mg elemental magnesium daily over 3–6 months, measuring attack frequency as the primary outcome. Results across trials showed consistent reductions in monthly attack frequency, with the most robust effects seen in patients with confirmed low magnesium status at baseline. Gröber et al. (2015) provide a comprehensive review of the clinical evidence base for magnesium across multiple conditions, including neurological applications.

The Mechanism: Four Pathways

Magnesium's relevance to migraine biology is not confined to a single mechanism — it touches multiple pathways involved in migraine generation and propagation.

1. NMDA receptor antagonism: Magnesium is a physiological blocker of NMDA (N-methyl-D-aspartate) glutamate receptors — it occupies the channel pore in a voltage-dependent manner, preventing glutamate-driven calcium influx. NMDA receptor hyperactivation is implicated in cortical spreading depression (CSD), the wave of neuronal and glial depolarization that generates migraine aura and sensitizes the trigeminal pain pathway. Low magnesium levels reduce this blocking effect, lowering the threshold for CSD initiation. This is considered the primary mechanistic link between magnesium deficiency and migraine susceptibility.

2. Vascular tone regulation: Magnesium is a natural calcium channel antagonist and vasodilator. Low magnesium promotes excessive vasoconstriction and heightens vascular reactivity to vasoconstrictive triggers including serotonin and substance P — both relevant to migraine neurovascular events. Zhang et al. (2016) demonstrated that magnesium supplementation reduces both systolic and diastolic blood pressure in a meta-analysis of RCTs, with effects largest in those with low baseline magnesium — consistent with the vascular tone hypothesis relevant to migraine.

3. Platelet aggregation and serotonin release: Magnesium inhibits platelet aggregation and modulates serotonin release from platelets. Excessive platelet serotonin release is associated with migraine initiation in some patients, and low magnesium has been shown to increase platelet sensitivity to aggregation signals. This mechanism is more relevant for vasomotor migraine subtypes than for migraine with aura.

4. Mitochondrial energy metabolism: Migraines are associated with impaired mitochondrial energy production in cortical neurons, and some migraine susceptibility genes are mitochondrially expressed. Magnesium is required for ATP synthesis (ATP is active as the Mg²⁺-ATP complex) and for over 300 enzymatic reactions in cellular energy metabolism as documented by Schwalfenberg and Genuis (2017). Cortical neurons with compromised mitochondrial ATP production are more susceptible to CSD triggering — making magnesium deficiency-induced mitochondrial inefficiency a plausible contributor to migraine susceptibility.

Oral Trial Data: What the RCTs Actually Found

The three most-cited oral magnesium migraine prevention RCTs used different forms and populations but produced consistent directional results:

A 1996 randomized double-blind trial used 600 mg trimagnesium dicitrate (magnesium citrate) daily for 12 weeks in 81 migraine patients. Attack frequency in the magnesium group fell by 41.6% compared to baseline, versus 15.8% in placebo — a statistically significant difference. This trial established the dosing range and outcome magnitude that subsequent work confirmed.

A 1991 trial tested magnesium pyrrolidone carboxylate in women with menstrual migraine, finding significant reductions in pain score and the number of days with headache in the luteal phase — suggesting particular relevance for hormonally-triggered migraine, which is associated with magnesium depletion during the premenstrual period.

A 2008 crossover trial using magnesium citrate 600 mg/day for 8 weeks in migraine with aura found reductions in the frequency of migraine attacks and cortical spreading depression events, consistent with the NMDA receptor mechanism. As detailed in Magnesium and Anxiety: What 6 Clinical Trials Actually Found, the HPA axis and NMDA modulation pathways that matter for anxiety overlap substantially with migraine neurobiology — which is why migraine comorbidity with anxiety disorders is both common and mechanistically coherent.

A systematic review published in 2016 covering nine randomized trials concluded that oral magnesium is effective for migraine prevention and is well-tolerated at standard doses, with the primary adverse effect being loose stools at doses above 400 mg elemental — a form-dependent effect discussed below.

Why Form Matters: Citrate and Glycinate vs. Oxide

The clinical trials that showed significant migraine prevention used bioavailable magnesium forms — primarily citrate, and in some cases glycinate. Magnesium oxide, which is the cheapest and most commonly sold form in mass-market supplements, absorbs poorly. At standard doses, magnesium oxide delivers roughly 4% elemental magnesium to systemic circulation. Citrate and glycinate both achieve substantially higher bioavailability — typically 60–80% — which matters when the therapeutic goal requires reaching a minimum tissue threshold for NMDA receptor modulation and cellular energy support.

As covered in Magnesium Glycinate: The Form That Gets Absorbed, the glycinate chelate binds magnesium to glycine — an amino acid that functions as an inhibitory neurotransmitter — potentially offering additional neurological benefit relevant to migraine biology beyond magnesium delivery alone. Glycinate is also the form least likely to cause gastrointestinal side effects, which is relevant at the 300–600 mg elemental doses used in migraine trials.

The dose calculation matters here: most magnesium glycinate supplements are dosed at 200–400 mg of the chelated compound, which delivers roughly 25–50 mg elemental magnesium per capsule. Reaching the 300–600 mg elemental doses used in clinical trials typically requires 4–8 capsules of standard-strength glycinate per day, or a dedicated high-dose formulation. Reviewing the Magnesium Glycinate Dosage Guide for the correct calculation is worthwhile before attempting a migraine prevention protocol.

Who Benefits Most

Several migraine subpopulations appear particularly responsive to magnesium supplementation based on the clinical evidence:

• Migraine with aura: The NMDA-CSD mechanism is most directly relevant here, and trials have shown stronger effects in patients with aura compared to migraine without aura.
• Menstrual migraine: Magnesium levels fall in the luteal phase and nadir premenstrually. Women with cyclically-triggered migraines showed significant benefit in the 1991 trial, and the deficiency mechanism in this population is well-established.
• Confirmed magnesium deficiency: Patients with documented low ionized serum or intracellular magnesium consistently show larger treatment effects than unselected migraine patients — consistent with the deficiency-correction model of mechanism.
• Frequent attackers (4+ per month): Prevention trials are powered for patients with moderate to high attack frequency. Evidence for efficacy in occasional migraine sufferers (1–3 per month) is thinner.
• Patients seeking non-pharmaceutical prophylaxis: The safety profile of magnesium glycinate is favorable — principal risk is GI softening at high doses, resolved by dose adjustment or splitting. This contrasts favorably with topiramate, propranolol, and valproate alternatives, which carry more significant side effect profiles.

Practical Takeaways

• Magnesium deficiency is significantly more prevalent in migraine patients than in headache-free controls; measuring ionized serum magnesium (not total serum) provides a better indication of deficiency status.
• The primary mechanism involves NMDA receptor blockade — low magnesium lowers the cortical spreading depression threshold that triggers migraine aura and trigeminal sensitization.
• Clinical trials used 300–600 mg elemental magnesium daily for 3–6 months; attack frequency reductions of 30–45% were consistently observed compared to placebo.
• Form matters substantially: citrate and glycinate forms deliver 10–20x the bioavailability of oxide at equivalent label doses.
• Response is strongest in patients with aura, menstrual migraine, and confirmed deficiency.
• Onset of prevention benefit typically requires 8–12 weeks of consistent supplementation before full effect is apparent — consistent with gradual tissue repletion timelines.

Bottom Line

Among supplement-based migraine interventions, magnesium has one of the more coherent evidence profiles: a plausible multi-pathway mechanism, documented deficiency prevalence in the target population, and consistent positive results across multiple randomized trials at doses achievable with high-bioavailability forms. The evidence quality is not equivalent to established pharmaceutical prophylactics, and head-to-head trials are limited, but the risk-to-benefit ratio is favorable given magnesium's safety profile. For individuals with frequent migraines — particularly those with aura or menstrual trigger patterns — a properly dosed glycinate or citrate protocol at 300–600 mg elemental daily is a reasonable, evidence-supported first-line intervention to evaluate over a 3-month trial period. Veronese et al. (2021) further support the safety and tolerability profile of magnesium supplementation across clinical populations, reinforcing its use in long-term protocols.

References

1. Schwalfenberg GK, Genuis SJ. "The importance of magnesium in clinical healthcare." Scientifica. 2017;2017:4179326. [Source]
2. Abbasi B, et al. "The effect of magnesium supplementation on primary insomnia in elderly." J Res Med Sci. 2012;17(12):1161–1169. [Source]
3. Gröber U, et al. "Magnesium in prevention and therapy." Nutrients. 2015;7(9):8199–8226. [Source]
4. Zhang X, et al. "Effects of magnesium supplementation on blood pressure: a meta-analysis of randomized double-blind placebo-controlled trials." Hypertension. 2016;68(2):324–333. [Source]
5. Veronese N, et al. "Effect of magnesium supplementation on oxidative stress in humans: a systematic review." Eur J Nutr. 2021;60(4):2049–2063. [Source]

---

---